Sign in or register to access exclusive content on this site
REGISTER

Home | Metabolism | Phenylketonuria (PKU) | Congress activities | The American College of Medical Genetics (ACMG) | ACMG 2025 poster: Interim results from the APHENITY extension study: Sepiapterin reduces blood Phe with improved dietary Phe tolerance in participants with phenylketonuria

ACMG 2025 poster: Interim results from the APHENITY extension study: Sepiapterin reduces blood Phe with improved dietary Phe tolerance in participants with phenylketonuria

This poster, presented at ACMG 2025, describes interim results from the ongoing APHENITY extension study, which evaluated the effect of sepiapterin on dietary Phe tolerance in a broad population of phenylketonuria (PKU) participants

  • Learn more about the updated APHENITY study results, including findings from the extension study of participants not involved in the original trial
  • Understand the long-term efficacy of sepiapterin on dietary Phe tolerance in participants of all ages and PKU disease severity
  • Review the safety profile of sepiapterin in this ongoing study
Always consult the prescribing information before prescribing any products

MED-US-CORP-2500008 | November 2025

This poster was developed and funded by PTC Therapeutics for ACMG 2025.

Fast-track access

Don't have an NPI number? Switch to manual verification
MED-US-CORP-2600009 | September 2026

Register now:

This field is for validation purposes and should be left unchanged.
  • This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:
    Marketing permissions - 1(Required)
    Marketing permissions - 2(Required)
    Keep me updated on the latest MEDhub content available*(Required)
* indicates a required field
Back to NPI verification

PTC will delete immediately the information provided if we cannot confirm you are healthcare professional. Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data: https://ptcprivacy.com/. For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at: Dataprivacy@ptcbio.com.

You can opt-out from PTC updates at any time by clicking the 'unsubscribe' link at the bottom of any email.

MED-US-CORP-2600009 | September 2026
MED-US-PKU-2600006 | February 2026

Welcome to MEDhub

A website for healthcare professionals, provided by PTC Therapeutics

This educational website provides you with the latest scientific data and expert insights on the diagnosis and management of a range of rare diseases across the neuromuscular system, central nervous system, and other areas

This website may include scientific information about investigational and unlicensed products not approved for use within your country. Please refer to local regulatory guidance for country-specific information

© 2026 PTC Therapeutics. All rights reserved | MED-US-CORP-2600001 | February 2026

This content is protected.

To view it please enter your email address or NPI number below:

Register here to access the content on the site

MED-US-CORP-2600009 | September 2026

COMING SOON

The content you are trying to access is not currently available.

We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.